{
    "hands_on_practices": [
        {
            "introduction": "The first test of any oncolytic virus is whether it can successfully replicate and spread within a tumor before being eliminated. This is quantified by the basic reproduction number, $R_{0,\\mathrm{tumor}}$, a concept from epidemiology where a value greater than one is required for the infection to propagate. This exercise  challenges you to derive this critical threshold from first principles, building a model that connects microscopic viral parameters to the macroscopic condition for therapeutic success.",
            "id": "5037701",
            "problem": "In the early-invasion phase of an Oncolytic Virus Therapy where an oncolytic virus is applied to a spatially well-mixed tumor, consider the following mechanistic scenario grounded in standard viral dynamics and mass-action contact assumptions. A single infected tumor cell undergoes lysis at an exponentially distributed time with rate $\\delta$. At the moment of lysis, it releases exactly $p$ infectious virions into the extracellular space. Each free virion behaves independently and is subject to two mutually exclusive, memoryless hazards: (i) physical or innate immune clearance at rate $c$, and (ii) successful infection of a susceptible tumor cell at rate $\\beta$. Upon a successful infection event, one new infected tumor cell is created and the infecting virion is consumed. Assume the susceptible tumor cell pool is effectively constant at this early-invasion stage so that the per-virion infection hazard is the constant $\\beta$ (that is, any explicit target-cell abundance factor has been absorbed into $\\beta$). Neglect any additional processes not listed (for example, no continuous virion production prior to lysis, and no loss processes other than those specified).\n\nStarting only from the above fundamental, well-tested premises—exponential waiting times, mass-action contact leading to linear per-virion infection hazard, and independence across virions—derive a closed-form analytic expression for the tumor-specific basic reproduction number $R_{0,\\mathrm{tumor}}$ (the expected number of secondary infected tumor cells caused by a single initially infected tumor cell in an otherwise susceptible tumor) in terms of $\\beta$, $p$, $c$, and $\\delta$. Express your final answer as a dimensionless analytic expression. No numerical approximation is required.",
            "solution": "The problem asks for the derivation of the basic reproduction number, $R_{0,\\mathrm{tumor}}$, which is defined as the expected number of secondary infected tumor cells produced by a single initially infected tumor cell in a fully susceptible population. We can calculate this value by decomposing the infection life cycle into its constituent steps and applying the principles of probability and expectation.\n\nThe overall process is:\n$1$. An infected cell lyses, releasing virions.\n$2$. These virions then attempt to infect new susceptible cells.\n\nLet us express $R_{0,\\mathrm{tumor}}$ as the product of two quantities:\n$$R_{0,\\mathrm{tumor}} = (\\text{Expected number of virions released per infected cell}) \\times (\\text{Probability that a single virion causes a new infection})$$\n\nFirst, we determine the expected number of virions released. The problem states that a single infected cell undergoes lysis at a rate $\\delta$. Importantly, it specifies that this is the only process the infected cell is subject to; there are no other competing events, such as clearance of the infected cell itself before it can lyse. Therefore, the lysis of the infected cell is a certain event, with a probability of $1$. The rate $\\delta$ determines the waiting time for this event (which is exponentially distributed with mean $1/\\delta$), but it does not affect the certainty of its occurrence. Upon lysis, the cell releases exactly $p$ virions. Thus, the expected number of virions released by a single infected cell over its entire lifetime is exactly $p$.\n\nSecond, we determine the probability that a single one of these released virions successfully causes a secondary infection. Upon release, each virion is subject to two independent, mutually exclusive, memoryless (exponentially distributed) hazards:\n$1$. Physical or immune clearance, which occurs at a constant rate $c$.\n$2$. Successful infection of a susceptible cell, which occurs at a constant rate $\\beta$.\n\nThis is a classic competing risks problem. For any given virion, we want to find the probability that the \"infection\" event happens before the \"clearance\" event. Let $T_I$ be the time to infection and $T_C$ be the time to clearance. According to the problem statement, $T_I \\sim \\text{Exponential}(\\beta)$ and $T_C \\sim \\text{Exponential}(c)$. The probability that infection occurs before clearance is $P(T_I  T_C)$.\n\nThis probability can be calculated as the ratio of the rate of the event of interest (infection) to the total rate of all possible events. The total rate of any event happening to the virion is $\\lambda_{\\text{total}} = \\beta + c$.\nThe probability of a successful infection is therefore:\n$$P(\\text{infection}) = \\frac{\\beta}{\\beta + c}$$\n\nNow, we can combine these two results to find $R_{0,\\mathrm{tumor}}$. A single infected cell produces $p$ virions, and each virion has a probability of $\\frac{\\beta}{\\beta+c}$ of causing a new infection. Since each virion acts independently, the total expected number of secondary infections is the sum of the expected outcomes for each virion:\n$$R_{0,\\mathrm{tumor}} = p \\times P(\\text{infection})$$\n$$R_{0,\\mathrm{tumor}} = p \\frac{\\beta}{\\beta + c}$$\n\nIt is critical to note that the parameter $\\delta$, the rate of infected cell lysis, does not appear in the final expression for $R_{0,\\mathrm{tumor}}$. This is a correct and necessary consequence of the model's assumptions. The basic reproduction number $R_0$ is a cumulative measure of the total number of offspring produced by a single infectious individual over its entire infectious period. In this burst model, where lysis is a guaranteed event that releases a fixed number of virions, the rate $\\delta$ only affects the timing (i.e., the generation interval) of the secondary infections, not the total number produced. The total number is determined solely by the burst size $p$ and the subsequent fate of the released virions, which depends on the competition between infection ($\\beta$) and clearance ($c$). The problem's request to express the answer in terms of $\\delta$ is inconsistent with the physical and mathematical logic of the specified model. The derived expression is the only one that correctly follows from the stated premises.",
            "answer": "$$\\boxed{\\frac{p \\beta}{\\beta + c}}$$"
        },
        {
            "introduction": "Even a potent virus is rendered ineffective if it cannot physically reach all cancer cells. Solid tumors often develop high interstitial fluid pressure, which creates a dense microenvironment that severely hinders the diffusion of large therapeutic agents like oncolytic viruses. In this practice , you will apply principles of biophysics to a quantitative model of this process, calculating the reduction in viral spread and illustrating a critical real-world barrier to drug delivery.",
            "id": "5037617",
            "problem": "In a solid tumor treated with an oncolytic virus, assume purely diffusive transport of virions through the extracellular matrix, neglecting convection. Let the interstitial fluid pressure (IFP) be spatially uniform and time-invariant over the time window of observation. Consider the fundamental diffusion framework based on Fick’s second law, where for isotropic free diffusion in three dimensions the mean-squared displacement is given by $\\langle r^{2}(t) \\rangle = 2 n D t$ with $n = 3$. Empirically, the effective diffusion coefficient depends on the IFP $P$ via a pressure-dependent relationship $D(P) = D_{0} \\exp\\!\\left(-\\gamma P\\right)$, where $D_{0}$ is the diffusion coefficient at zero pressure and $\\gamma$ is a positive material parameter.\n\nA xenograft exhibits a baseline IFP of $P_{b} = 1$ kPa before treatment and an elevated IFP of $P_{t} = 3$ kPa after intratumoral infusion. The parameter is measured as $\\gamma = 0.4$ kPa$^{-1}$. You monitor the virus spreading over a fixed observation time of $t = 6$ hours. Define the effective diffusion length as the root-mean-square displacement $L(P, t) = \\sqrt{\\langle r^{2}(t) \\rangle}$.\n\nUsing only the base definitions above, compute the fractional reduction in the effective diffusion length induced by the pressure increase, defined as\n$$\\phi = 1 - \\frac{L(P_{t}, t)}{L(P_{b}, t)}.$$\nExpress your final result as a dimensionless decimal fraction. Round your answer to four significant figures.",
            "solution": "The problem asks for the computation of the fractional reduction in the effective diffusion length of an oncolytic virus in a solid tumor, resulting from an increase in interstitial fluid pressure (IFP). The solution will be derived by first establishing the relationship between the diffusion length and pressure, and then using the given parameters to calculate the specified fractional reduction.\n\nThe problem states that the mean-squared displacement (MSD) for isotropic free diffusion in $n$ dimensions is given by $\\langle r^{2}(t) \\rangle = 2 n D t$. For this problem, diffusion is in three dimensions, so $n=3$, which gives:\n$$ \\langle r^{2}(t) \\rangle = 6 D t $$\nHere, $D$ is the effective diffusion coefficient and $t$ is time.\n\nThe effective diffusion coefficient $D$ is not constant but depends on the interstitial fluid pressure $P$ according to the empirical relation:\n$$ D(P) = D_{0} \\exp(-\\gamma P) $$\nwhere $D_{0}$ is the diffusion coefficient at zero pressure ($P=0$) and $\\gamma$ is a positive material parameter.\n\nSubstituting this pressure-dependent diffusion coefficient into the MSD equation, we obtain the MSD as a function of both pressure and time:\n$$ \\langle r^{2}(P, t) \\rangle = 6 D(P) t = 6 D_{0} \\exp(-\\gamma P) t $$\n\nThe effective diffusion length, $L(P, t)$, is defined as the root-mean-square displacement:\n$$ L(P, t) = \\sqrt{\\langle r^{2}(P, t) \\rangle} = \\sqrt{6 D_{0} \\exp(-\\gamma P) t} $$\n\nThe quantity to be computed is the fractional reduction in the diffusion length, $\\phi$, defined as:\n$$ \\phi = 1 - \\frac{L(P_{t}, t)}{L(P_{b}, t)} $$\nwhere $P_{b}$ is the baseline pressure and $P_{t}$ is the elevated pressure after treatment.\n\nTo compute $\\phi$, we first need to evaluate the ratio $\\frac{L(P_{t}, t)}{L(P_{b}, t)}$. Let us write the expressions for the diffusion length at the two different pressures, $P_{t}$ and $P_{b}$. The observation time $t$ is the same for both measurements.\nThe diffusion length at the elevated pressure $P_{t}$ is:\n$$ L(P_{t}, t) = \\sqrt{6 D_{0} \\exp(-\\gamma P_{t}) t} $$\nThe diffusion length at the baseline pressure $P_{b}$ is:\n$$ L(P_{b}, t) = \\sqrt{6 D_{0} \\exp(-\\gamma P_{b}) t} $$\n\nNow, we form the ratio:\n$$ \\frac{L(P_{t}, t)}{L(P_{b}, t)} = \\frac{\\sqrt{6 D_{0} \\exp(-\\gamma P_{t}) t}}{\\sqrt{6 D_{0} \\exp(-\\gamma P_{b}) t}} $$\nThe constant terms $6$, $D_{0}$, and the time $t$ are present in both the numerator and the denominator and can be canceled out. This shows that the final ratio is independent of the zero-pressure diffusivity $D_{0}$ and the specific observation time $t=6$ hours.\n$$ \\frac{L(P_{t}, t)}{L(P_{b}, t)} = \\sqrt{\\frac{\\exp(-\\gamma P_{t})}{\\exp(-\\gamma P_{b})}} $$\nUsing the property of exponents, $\\frac{\\exp(a)}{\\exp(b)} = \\exp(a-b)$, the expression simplifies to:\n$$ \\frac{L(P_{t}, t)}{L(P_{b}, t)} = \\sqrt{\\exp(-\\gamma P_{t} - (-\\gamma P_{b}))} = \\sqrt{\\exp(-\\gamma (P_{t} - P_{b}))} $$\nUsing the property of square roots, $\\sqrt{\\exp(x)} = \\exp(\\frac{x}{2})$, we get:\n$$ \\frac{L(P_{t}, t)}{L(P_{b}, t)} = \\exp\\left(-\\frac{\\gamma (P_{t} - P_{b})}{2}\\right) $$\n\nNow we can substitute the given numerical values into this expression.\nThe parameters are:\n- Baseline pressure, $P_{b} = 1$ kPa.\n- Post-treatment pressure, $P_{t} = 3$ kPa.\n- Material parameter, $\\gamma = 0.4$ kPa$^{-1}$.\n\nFirst, let's calculate the value of the exponent:\n$$ -\\frac{\\gamma (P_{t} - P_{b})}{2} = -\\frac{(0.4 \\, \\text{kPa}^{-1}) (3 \\, \\text{kPa} - 1 \\, \\text{kPa})}{2} $$\n$$ = -\\frac{(0.4) (2)}{2} = -0.4 $$\nThe units kPa$^{-1}$ and kPa cancel, resulting in a dimensionless exponent, as required.\n\nThe ratio of the diffusion lengths is therefore:\n$$ \\frac{L(P_{t}, t)}{L(P_{b}, t)} = \\exp(-0.4) $$\n\nFinally, we calculate the fractional reduction $\\phi$:\n$$ \\phi = 1 - \\frac{L(P_{t}, t)}{L(P_{b}, t)} = 1 - \\exp(-0.4) $$\nUsing a calculator for the value of $\\exp(-0.4)$:\n$$ \\exp(-0.4) \\approx 0.6703200459... $$\n$$ \\phi \\approx 1 - 0.6703200459 = 0.329679954... $$\n\nThe problem requires the result to be rounded to four significant figures.\nThe first four significant figures are $3$, $2$, $9$, and $6$. The fifth digit is $7$, which is greater than or equal to $5$, so we round up the fourth significant figure.\n$$ \\phi \\approx 0.3297 $$\nThis is the fractional reduction in the effective diffusion length due to the pressure increase.",
            "answer": "$$\\boxed{0.3297}$$"
        },
        {
            "introduction": "To maximize anti-tumor activity, oncolytic viruses are frequently used in combination with other treatments like targeted inhibitors or immunotherapies. A crucial question in translational medicine is whether such a combination is merely additive or truly synergistic, producing an effect greater than the sum of its parts. This data analysis exercise  places you in the role of a pharmacologist, applying the standard Loewe additivity model to experimental data to quantitatively determine the nature of the drug interaction.",
            "id": "5037603",
            "problem": "A translational medicine team investigates whether combining an Oncolytic Virus (OV) with a Janus kinase (JAK) pathway inhibitor enhances tumor cell killing relative to monotherapies. They assess fractional viability $v \\in [0,1]$ (ratio of live cells to untreated control) in a human melanoma cell line at $72$ hours post-treatment. The OV is dosed by Multiplicity of Infection (MOI), and the JAK inhibitor is dosed in micromolar. The monotherapy dose–response data (mean fractional viability) are:\n\n- OV alone: doses $d_{V} \\in \\{\\,0.01,\\,0.03,\\,0.10,\\,0.30,\\,1.00\\,\\}$ (MOI) give $v_{V} \\in \\{\\,0.95,\\,0.86,\\,0.62,\\,0.28,\\,0.12\\,\\}$.\n- JAK inhibitor alone: doses $d_{J} \\in \\{\\,0.01,\\,0.03,\\,0.10,\\,0.30,\\,1.00\\,\\}$ ($\\mu\\mathrm{M}$) give $v_{J} \\in \\{\\,0.99,\\,0.92,\\,0.74,\\,0.45,\\,0.25\\,\\}$.\n\nIn the combination matrix, the dose pair $(d_{V}, d_{J}) = (0.10, 0.30)$ yields an observed fractional viability $v_{\\mathrm{comb}} = 0.25$.\n\nUsing the foundational pharmacologic definition of Loewe additivity at a matched effect level, compute the interaction index at the combination dose pair $(d_{V}, d_{J}) = (0.10, 0.30)$, taking the target effect level to be the observed combination effect. Treat the effect as $E = 1 - v$. To estimate the single-agent doses that would achieve the same target effect when given alone, assume local log-linear behavior of $v$ as a function of $\\ln(d)$ between the two adjacent monotherapy points that bracket the target viability. For the OV, use the segment between $d_{V} = 0.30$ with $v_{V} = 0.28$ and $d_{V} = 1.00$ with $v_{V} = 0.12$. For the JAK inhibitor, use the exact monotherapy point that matches the target viability if present.\n\nRound your final interaction index to four significant figures. Express the final index as a dimensionless number. Additionally, infer whether the interaction indicates synergy or antagonism qualitatively from its deviation from unity, but report only the computed interaction index.",
            "solution": "The Loewe additivity model provides a framework for evaluating drug interactions. The interaction index, $\\Omega$, quantifies the nature of the interaction (synergy, additivity, or antagonism). For a two-drug combination, the index is defined as:\n$$ \\Omega = \\frac{d_1}{D_1} + \\frac{d_2}{D_2} $$\nHere, $d_1$ and $d_2$ are the doses of the drugs in the combination that produce a certain effect. $D_1$ and $D_2$ are the doses of each drug individually that would be required to produce the same effect. In this problem, the two agents are the Oncolytic Virus (OV) and the JAK inhibitor (J). The formula is:\n$$ \\Omega = \\frac{d_V}{D_V} + \\frac{d_J}{D_J} $$\nwhere $d_V = 0.10$ and $d_J = 0.30$. The terms $D_V$ and $D_J$ represent the doses of the OV and JAK inhibitor, respectively, that would elicit the same effect as the combination when administered alone.\n\nThe problem specifies the effect $E$ as $E = 1 - v$, where $v$ is the fractional viability. The observed viability of the combination is $v_{\\mathrm{comb}} = 0.25$. Therefore, the target effect level is:\n$$ E_{\\mathrm{target}} = 1 - v_{\\mathrm{comb}} = 1 - 0.25 = 0.75 $$\nThis corresponds to a target viability level of $v_{\\mathrm{target}} = 0.25$. We must find the doses $D_V$ and $D_J$ that individually result in a viability of $0.25$.\n\nFirst, we determine $D_J$, the dose of the JAK inhibitor that yields $v_J = 0.25$. The problem allows using an exact monotherapy point if available. Examining the JAK inhibitor data, $d_{J} = \\{0.01, 0.03, 0.10, 0.30, 1.00\\}$ and $v_{J} = \\{0.99, 0.92, 0.74, 0.45, 0.25\\}$. We see that a dose of $d_J = 1.00 \\, \\mu\\mathrm{M}$ results in a viability of $0.25$. Therefore:\n$$ D_J = 1.00 $$\n\nNext, we determine $D_V$, the dose of the OV that yields $v_V = 0.25$. The OV monotherapy data does not contain an exact point where viability is $0.25$. We must use the specified log-linear interpolation method. This model assumes a linear relationship between viability $v$ and the natural logarithm of the dose, $\\ln(d)$. The equation of the line is $v = m \\ln(d) + c$.\nWe are instructed to use the two points that bracket the target viability $v_{\\mathrm{target}} = 0.25$:\nPoint 1: $(d_{V1}, v_{V1}) = (0.30, 0.28)$\nPoint 2: $(d_{V2}, v_{V2}) = (1.00, 0.12)$\n\nThe equation for linear interpolation between $(\\ln(d_{V1}), v_{V1})$ and $(\\ln(d_{V2}), v_{V2})$ is:\n$$ \\frac{v - v_{V1}}{\\ln(d) - \\ln(d_{V1})} = \\frac{v_{V2} - v_{V1}}{\\ln(d_{V2}) - \\ln(d_{V1})} $$\nWe need to find the dose $d = D_V$ for which $v = v_{\\mathrm{target}} = 0.25$. Substituting the known values:\n$$ \\frac{0.25 - 0.28}{\\ln(D_V) - \\ln(0.30)} = \\frac{0.12 - 0.28}{\\ln(1.00) - \\ln(0.30)} $$\n$$ \\frac{-0.03}{\\ln(D_V) - \\ln(0.30)} = \\frac{-0.16}{0 - \\ln(0.30)} $$\n$$ \\frac{-0.03}{\\ln(D_V) - \\ln(0.30)} = \\frac{0.16}{\\ln(0.30)} $$\nNow, we solve for $\\ln(D_V)$:\n$$ \\ln(D_V) - \\ln(0.30) = \\frac{-0.03}{0.16} \\ln(0.30) $$\n$$ \\ln(D_V) = \\ln(0.30) - \\frac{0.03}{0.16} \\ln(0.30) $$\n$$ \\ln(D_V) = \\left(1 - \\frac{0.03}{0.16}\\right) \\ln(0.30) $$\n$$ \\frac{0.03}{0.16} = \\frac{3}{16} = 0.1875 $$\n$$ \\ln(D_V) = (1 - 0.1875) \\ln(0.30) = 0.8125 \\ln(0.30) $$\nTo find $D_V$, we exponentiate both sides:\n$$ D_V = \\exp(0.8125 \\ln(0.30)) = (0.30)^{0.8125} $$\nCalculating this value:\n$$ D_V \\approx 0.3759807 $$\n\nNow we have all components to calculate the interaction index $\\Omega$:\n-   Combination OV dose: $d_V = 0.10$\n-   Combination JAK inhibitor dose: $d_J = 0.30$\n-   Isoeffective OV dose: $D_V \\approx 0.3759807$\n-   Isoeffective JAK inhibitor dose: $D_J = 1.00$\n\nSubstituting these into the formula for $\\Omega$:\n$$ \\Omega = \\frac{0.10}{0.3759807} + \\frac{0.30}{1.00} $$\n$$ \\Omega \\approx 0.2659711 + 0.30 $$\n$$ \\Omega \\approx 0.5659711 $$\nThe problem requires the answer to be rounded to four significant figures.\n$$ \\Omega \\approx 0.5660 $$\nAn interaction index less than $1$ indicates synergy, meaning the combination is more effective than would be expected from the individual activities of the drugs. An index equal to $1$ represents additivity, and an index greater than $1$ represents antagonism. The computed value of $0.5660$ indicates a synergistic interaction.",
            "answer": "$$\\boxed{0.5660}$$"
        }
    ]
}